317 related articles for article (PubMed ID: 22001608)
1. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
Bhandari KH; Newa M; Chapman J; Doschak MR
J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin.
Bhandari KH; Newa M; Uludag H; Doschak MR
Int J Pharm; 2010 Jul; 394(1-2):26-34. PubMed ID: 20412845
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis.
Bhandari KH; Asghar W; Newa M; Jamali F; Doschak MR
Curr Drug Deliv; 2015; 12(1):98-107. PubMed ID: 25860966
[TBL] [Abstract][Full Text] [Related]
4. Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats.
Yang Y; Aghazadeh-Habashi A; Panahifar A; Wu Y; Bhandari KH; Doschak MR
Drug Deliv Transl Res; 2017 Aug; 7(4):482-496. PubMed ID: 28721611
[TBL] [Abstract][Full Text] [Related]
5. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection.
Youn YS; Kwon MJ; Na DH; Chae SY; Lee S; Lee KC
J Control Release; 2008 Jan; 125(1):68-75. PubMed ID: 18023905
[TBL] [Abstract][Full Text] [Related]
6. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy.
Youn YS; Jung JY; Oh SH; Yoo SD; Lee KC
J Control Release; 2006 Sep; 114(3):334-42. PubMed ID: 16884808
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization and biodistribution studies of (125)I-radioiodinated di-PEGylated bone targeting salmon calcitonin analogue in healthy rats.
Yang Y; Bhandari KH; Panahifar A; Doschak MR
Pharm Res; 2014 May; 31(5):1146-57. PubMed ID: 24357414
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol.
Cheng W; Lim LY
J Pharm Sci; 2009 Apr; 98(4):1438-51. PubMed ID: 18704953
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats.
Lee KC; Park MO; Na DH; Youn YS; Lee SD; Yoo SD; Lee HS; DeLuca PP
Calcif Tissue Int; 2003 Dec; 73(6):545-9. PubMed ID: 14508623
[TBL] [Abstract][Full Text] [Related]
10. Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate.
Ryan SM; Wang X; Mantovani G; Sayers CT; Haddleton DM; Brayden DJ
J Control Release; 2009 Apr; 135(1):51-9. PubMed ID: 19168100
[TBL] [Abstract][Full Text] [Related]
11. PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights.
Ryan SM; FrÃas JM; Wang X; Sayers CT; Haddleton DM; Brayden DJ
J Control Release; 2011 Jan; 149(2):126-32. PubMed ID: 20946924
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety.
Cheng W; Lim LY
J Pharm Pharmacol; 2010 Mar; 62(3):296-304. PubMed ID: 20487211
[TBL] [Abstract][Full Text] [Related]
13. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
[TBL] [Abstract][Full Text] [Related]
14. A rat osteoporotic spine model for the evaluation of bioresorbable bone cements.
Wang ML; Massie J; Perry A; Garfin SR; Kim CW
Spine J; 2007; 7(4):466-74. PubMed ID: 17630145
[TBL] [Abstract][Full Text] [Related]
15. High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation.
Youn YS; Na DH; Lee KC
J Control Release; 2007 Feb; 117(3):371-9. PubMed ID: 17207880
[TBL] [Abstract][Full Text] [Related]
16. Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT).
Kotak DJ; Devarajan PV
Nanomedicine; 2020 Feb; 24():102153. PubMed ID: 31988038
[TBL] [Abstract][Full Text] [Related]
17. Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: In vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats.
Jeon OC; Seo DH; Kim HS; Byun Y; Park JW
Eur J Pharm Sci; 2016 Jan; 82():1-10. PubMed ID: 26542347
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of polyethylene-glycol-modified salmon calcitonins.
Lee KC; Tak KK; Park MO; Lee JT; Woo BH; Yoo SD; Lee HS; DeLuca PP
Pharm Dev Technol; 1999 May; 4(2):269-75. PubMed ID: 10231888
[TBL] [Abstract][Full Text] [Related]
19. Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin.
DeLuca PP; Dani BA
AAPS PharmSci; 2001; 3(4):E27. PubMed ID: 12049490
[TBL] [Abstract][Full Text] [Related]
20. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis.
Liu Y; Yu P; Peng X; Huang Q; Ding M; Chen Y; Jin R; Xie J; Zhao C; Li J
J Control Release; 2019 Jun; 304():39-50. PubMed ID: 31054990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
